Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 672063

Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy


Bacalja, Jasna; Ulamec, Monika; Rako, Duje; Bošković, Lidija; Trnski, Davor; Vrdoljak, Eduard; Krušlin, Božo
Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy // In vivo, 27 (2013), 3; 545-549 (recenziran, članak, stručni)


CROSBI ID: 672063 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy

Autori
Bacalja, Jasna ; Ulamec, Monika ; Rako, Duje ; Bošković, Lidija ; Trnski, Davor ; Vrdoljak, Eduard ; Krušlin, Božo

Izvornik
In vivo (0258-851X) 27 (2013), 3; 545-549

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
CHOP; MALT lymphoma; chemotherapy; rituximab; urinary bladder

Sažetak
A 48-year-old male underwent a routine ultrasound examination. A tumour mass in the urinary bladder was found and a transurethral biopsy was performed. Pathohistological examination revealed MALT lymphoma. Results of computed tomographic scan, positron emission tomography scan and bone marrow biopsy defined the tumour as primary malignant lymphoma of the urinary bladder. The patient received eight cycles of chemo- immunotherapy (CHOP) and radiotherapy. Five months after therapy, there is a partial radiological remission, but with metabolic progression of the tumour. To our knowledge, this is the first case of MALT lymphoma of the urinary bladder with chemo-immunotherapy and radiotherapy resistance.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekti:
108-1081870-1884 - Razvojna neuropatologija genetskih malformacija moždane kore čovjeka (Krušlin, Božo, MZOS ) ( CroRIS)
216-0000000-0484 - Dvostruki model ovarijalne kancerogeneze - molekularna i morfološka studija (Tomić, Snježana, MZOS ) ( CroRIS)

Ustanove:
Medicinski fakultet, Zagreb,
KBC "Sestre Milosrdnice",
KBC Split,
Klinička bolnica "Dubrava",
Medicinski fakultet, Split

Citiraj ovu publikaciju:

Bacalja, Jasna; Ulamec, Monika; Rako, Duje; Bošković, Lidija; Trnski, Davor; Vrdoljak, Eduard; Krušlin, Božo
Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy // In vivo, 27 (2013), 3; 545-549 (recenziran, članak, stručni)
Bacalja, J., Ulamec, M., Rako, D., Bošković, L., Trnski, D., Vrdoljak, E. & Krušlin, B. (2013) Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy. In vivo, 27 (3), 545-549.
@article{article, author = {Bacalja, Jasna and Ulamec, Monika and Rako, Duje and Bo\v{s}kovi\'{c}, Lidija and Trnski, Davor and Vrdoljak, Eduard and Kru\v{s}lin, Bo\v{z}o}, year = {2013}, pages = {545-549}, keywords = {CHOP, MALT lymphoma, chemotherapy, rituximab, urinary bladder}, journal = {In vivo}, volume = {27}, number = {3}, issn = {0258-851X}, title = {Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy}, keyword = {CHOP, MALT lymphoma, chemotherapy, rituximab, urinary bladder} }
@article{article, author = {Bacalja, Jasna and Ulamec, Monika and Rako, Duje and Bo\v{s}kovi\'{c}, Lidija and Trnski, Davor and Vrdoljak, Eduard and Kru\v{s}lin, Bo\v{z}o}, year = {2013}, pages = {545-549}, keywords = {CHOP, MALT lymphoma, chemotherapy, rituximab, urinary bladder}, journal = {In vivo}, volume = {27}, number = {3}, issn = {0258-851X}, title = {Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy}, keyword = {CHOP, MALT lymphoma, chemotherapy, rituximab, urinary bladder} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE





Contrast
Increase Font
Decrease Font
Dyslexic Font